Neurology Advisor

Oral Antiviral Xocova Approved for COVID-19 Postexposure Prophylaxis

The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
Business Wire

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...
Healio

Extended oral antibiotic prophylaxis may not reduce risk of PJI after TJA

Please provide your email address to receive an email when new articles are posted on . Extended oral antibiotic prophylaxis did not reduce infection rates after hip or knee arthroplasty. Infection ...
Healio

Extended oral antibiotic prophylaxis did not reduce infection rates after TJA

Please provide your email address to receive an email when new articles are posted on . Published results showed patients who were morbidly obese and received extended oral antibiotic prophylaxis ...
Medscape

New AHA Guidelines for Prevention of Infective Endocarditis

Pediatr Infect Dis J. 2008;27(7):647-648. From the beginning, the scientific basis for recommendations for endocarditis prophylaxis was not well established. The evidence supporting prophylaxis ...